30 minutes
The platform-based, venture-created, $100M+ Series A startup is now a fixture in Massachusetts biotech. However, most first-time founders come straight from academia and struggle to secure funding to demonstrate meaningful in-vivo efficacy of their product candidate. Since therapeutics' risk, time and scale of capital doesn't match the needs of angel investors, who will fund the next generation of great ideas and leaders? This panel will explore alternate forms of funding along with the critical role of mentors, advisory boards, and other support systems in navigating this landscape.


Ann DeWitt - General Partner, The Engine
Deborah Palestrant - Partner, Head of 4:59, 5AM Ventures
Raymond J. Tesi - President, Chief Executive Officer, ImmuneBio
Stephen Kennedy Smith - Principal, Park Agency, Kennedy Enterprises
Name Audience
Business Track